Trials / Completed
CompletedNCT03674866
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
A Canadian Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus CAN-TREAT (CANadian TREsiba AudiT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 662 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months. Data will be collected beginning 6 months before the participant started Tresiba® up to around 6 months after the participant started taking insulin degludec.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin degludec | Participants are treated with Tresiba® (insulin degludec) under conditions of routine care. |
Timeline
- Start date
- 2018-10-29
- Primary completion
- 2019-04-25
- Completion
- 2019-04-26
- First posted
- 2018-09-18
- Last updated
- 2019-12-06
Locations
32 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03674866. Inclusion in this directory is not an endorsement.